Explore Orforglipron dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator data.
Orforglipron is an investigational once-daily GLP-1 receptor agonist that is a small molecule, not a peptide — so it can be taken as a pill. It is sourced in research for weight and blood-sugar studies and ships as capsules or a powder.
Orforglipron activates the GLP-1 receptor like injectable GLP-1 peptides do, curbing appetite and improving glucose-dependent insulin release, but as a non-peptide it survives oral dosing.
Phase 2 and Phase 3 trials in obesity and type 2 diabetes have reported meaningful weight and A1C reductions, but orforglipron is not yet approved by any regulator.
Not FDA-approved. Investigational oral GLP-1 in Phase 3 trials; research-grade material for non-clinical use.
It is catalogued under Other Peptides on WPA.
The WPA community has not yet logged enough Orforglipron calculator sessions to publish dose, vial size, or bacteriostatic water distributions for it. This page therefore covers what is known about the compound itself; the usage charts fill in as researchers run the calculator.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.